SCULLY WILLIAM P purchased $30K of PRTA (indirect holdings)

SCULLY WILLIAM P purchased 3,500 indirectly-held shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.62 on 2026-08-07.

Original reporting
SEC EDGAR · SCULLY WILLIAM P
Published Aug 10, 2026, 7:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 7:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PRTA
Neutral
medium confidence
Mentioned
$PRTA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRTANeutralLow
01

Why it matters

A new insider open-market purchase was reported, but the filing does not include any operational or financial update that would directly change forward fundamentals.

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

The article does not disclose intent, timing constraints, or whether the purchase is part of a broader accumulation pattern, limiting signal strength.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10 after-hours/late session; transaction dated 2026-08-07

Background

This is an SEC Form 4 insider transaction disclosure for Prothena Corp. Public Ltd Co (PRTA).

Company-level read

Ticker impact

$PRTANeutralMedium confidence
Context

Prothena (PRTA) disclosed an open-market purchase by 10% owner William P. Scully: 3,500 shares at $8.6192 on 2026-08-07.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, but this transaction size and lack of accompanying corporate event typically do not reset valuation or risk materially.

Market effects

No sector-wide implication is provided; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by diversification or pre-existing plans; this filing also notes no pre-arranged 10b5-1 plan, which can cut both ways.

Key entities

  • PROTHENA CORP PUBLIC LTD CO

    Company subject of the Form 4 insider transaction disclosure.

  • SCULLY WILLIAM P

    10% owner who purchased 3,500 shares indirectly at $8.6192 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PRTAMedAI 8/10

Prothena Corporation plc: Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

Prothena reported Q3 2026 net loss of $16.5M and 9M net loss of $2.4M, with $272.2M in cash. Coramitug showed reduced hsCRP in Phase 2 trial. Roche and Novo highlight prasinezumab and coramitug for Parkinson's and ATTR-CM. Phase 3 trials expected to complete in 2029. Prothena has $650M in upfront payments and potential $2.25B in milestones. Preclinical programs include TDP-43 CYTOPE and PRX012-TfR.

$PRTAMed

Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Prothena Reports Third Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $12.0 million in the third quarter and net cash used in operating and investing activities was $8.9 million for the